CLAIMS

What is claimed is:

- 1. A method of modifying vasoactivity by regulating a soluble $A\beta$ pro-inflammatory pathway.
- 2. The method according to claim 1, further defined as upregulating the soluble $A\beta$ pro-inflammatory pathway.
- 3. The method according to claim 1, further defined as down-regulating the soluble $A\beta$ pro-inflammatory pathway.
- 4. A method of treating patients with vascular disease by modifying an intracellular soluble $A\beta$ proinflammatory pathway.
- 5. The method according to claim 4, wherein said modifying step is further defined as blocking target molecules of the soluble $A\beta$ pro-inflammatory pathway.
- 6. A pharmaceutical composition comprising an effective amount of a soluble $A\beta$ pro-inflammatory pathway regulator and a pharmaceutically effective carrier.
- 7. The pharmaceutical composition according to claim 6, wherein said soluble $A\beta$ pro-inflammatory pathway regulator blocks the activity of type I secretory PLA2.
- 8. The pharmaceutical composition according to claim 7, wherein said soluble $A\beta$ pro-inflammatory pathway regulator is a non-toxic derivative of oleyloxyethylphosphorylcholine or related compounds.





- 9. The pharmaceutical composition according to claim 6, wherein said soluble $A\beta$ pro-inflammatory pathway regulator blocks the activity of cytosolic PLA2.
- 10. The pharmaceutical composition according to claim 9, wherein said soluble A β pro-inflammatory pathway regulator is one from the group consisting essentially of methyl arachydonyl fluorophosphonate, AACOCF, or related compounds.
- 11. The pharmaceutical composition according to claim 6, wherein said soluble $A\beta$ pro-inflammatory pathway regulator blocks the activity of enzymes of the LOX family.
- 12. The pharmaceutical composition according to claim 11 wherein said soluble $A\beta$ pro-inflammatory pathway regulator is MK-886.
- 13. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator is MAP kinase inhibitor. Selected from the group consisting essentially of p38MAP kinase inhibitors and MEK1/2 inhibitors.
- 14. The pharmaceutical composition according to claim 6, wherein said soluble A β pro-inflammatory pathway regulator blocks the activity of enzymes of both the LOX and COX families.
- 15. The pharmaceutical composition according to claim 14, wherein said soluble $A\beta$ pro-inflammatory pathway regulator is one from the group consisting essentially of



ER-34122, BW-A4C or MK-886 in combination with non-toxic derivatives of NS-398.

- 16. A diagnostic method including the steps of detecting modification of the soluble $A\beta$ pro-inflammatory pathway.
- 17. The diagnostic method according to claim 16, wherein said detecting step further includes detecting any up-regulation of the soluble A β pro-inflammatory pathway.
- 18. The diagnostic method according to claim 16, wherein said detecting step further includes detecting any down-regulation of the soluble $A\beta$ pro-inflammatory pathway.
- 19. A method of modifying inflammatory reactions in microglia and neurons by regulating a soluble $A\beta$ proinflammatory pathway.
- 20. The method according to claim 19, further defined as upregulating the soluble $A\beta$ pro-inflammatory pathway.
- 21. The method according to claim 19, further defined as down-regulating the soluble $A\beta$ pro-inflammatory pathway.